CIK 0001641631 · Non-accelerated filer<br>Smaller reporting company
Beyond Air, Inc.
Sign in to watch- Ticker
- XAIR
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473812456
- Phone
- 516-665-8200
- Business address
- 900 STEWART AVENUE, SUITE 301, GARDEN CITY, NY, 11530
- Former names
- AIT Therapeutics, Inc., KokiCare, Inc.
- Open-market buys, last 90 days
- $62,352
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$62,352. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-13 | Lin Yi-Chien 10% owner | Purchase | +2,607 | $2.21 | $6K | 148,000 |
| 2026-10-01 | Lin Yi-Chien 10% owner | Purchase | +15,393 | $2.80 | $43K | 145,393 |
| 2026-09-30 | Lin Yi-Chien 10% owner | Purchase | +2,000 | $2.71 | $5K | 130,000 |
| 2026-09-29 | Lin Yi-Chien 10% owner | Purchase | +3,000 | $2.69 | $8K | 128,000 |
| 2026-07-29 | Goodman Robert Scott Chief Executive Officer | Purchase | +34,722 | $5.76 | $200K | 34,822 |
| 2026-07-29 | Goodman Robert Scott Chief Executive Officer | Purchase · Series A Warrants | +34,722 | 34,722 | ||
| 2026-07-29 | Goodman Robert Scott Chief Executive Officer | Purchase · Series B Warrants | +34,722 | 34,722 | ||
| 2026-07-29 | MOORHEAD DANIEL J Chief Financial Officer | Purchase | +4,340 | $5.76 | $25K | 4,340 |
| 2026-07-29 | MOORHEAD DANIEL J Chief Financial Officer | Purchase · Series A Warrant | +4,340 | 4,340 | ||
| 2026-07-29 | MOORHEAD DANIEL J Chief Financial Officer | Purchase · Series B Warrant | +4,340 | 4,340 | ||
| 2026-01-05 | MOORHEAD DANIEL J Chief Financial Officer | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2025-11-04 | Lee Yoori Director | Returned to the company · Stock Options (Right to buy) | −2,250 | 0 | ||
| 2025-11-04 | Lee Yoori Director | Grant or award · Stock Options (Right to buy) | +2,250 | 2,250 | ||
| 2025-11-04 | Lee Yoori Director | Returned to the company · Stock Options (Right to buy) | −2,000 | 0 | ||
| 2025-11-04 | Lee Yoori Director | Grant or award · Stock Options (Right to buy) | +2,000 | 2,000 | ||
| 2025-11-04 | Lee Yoori Director | Returned to the company · Stock Options (Right to buy) | −1,500 | 0 | ||
| 2025-11-04 | Lee Yoori Director | Grant or award · Stock Options (Right to buy) | +1,500 | 1,500 | ||
| 2025-11-04 | Lee Yoori Director | Returned to the company · Stock Options (Right to buy) | −1,250 | 0 | ||
| 2025-11-04 | Lee Yoori Director | Grant or award · Stock Options (Right to buy) | +1,250 | 1,250 | ||
| 2025-11-04 | Lee Yoori Director | Returned to the company · Stock Options (Right to buy) | −1,250 | 0 |
Page 1 of 17 · 328 trades